Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $34.1 million.

  • CG Oncology's Non-Current Assets rose 862711.0% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 127957.75%. This contributed to the annual value of $587000.0 for FY2024, which is 8866.14% down from last year.
  • CG Oncology's Non-Current Assets amounted to $34.1 million in Q3 2025, which was up 862711.0% from $28.4 million recorded in Q2 2025.
  • CG Oncology's 5-year Non-Current Assets high stood at $34.1 million for Q3 2025, and its period low was $391000.0 during Q3 2024.
  • Its 3-year average for Non-Current Assets is $12.1 million, with a median of $2.9 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 8866.14% in 2024, then skyrocketed by 862711.0% in 2025.
  • CG Oncology's Non-Current Assets (Quarter) stood at $5.2 million in 2023, then tumbled by 88.66% to $587000.0 in 2024, then soared by 5713.12% to $34.1 million in 2025.
  • Its Non-Current Assets was $34.1 million in Q3 2025, compared to $28.4 million in Q2 2025 and $27.0 million in Q1 2025.